Current cancer immunotherapy strategies primarily target programmed cell death-1 ligand-1 (PD-L1), chimeric antigen receptors, and cytotoxic T lymphocyte-associated antigen 4 [27, 28]; however, the effects of CAFs on tumor immunosuppression remain relatively unexplored. The gene discussed is CD274; the disease is cancer.